Why psoriasis trial monitoring matters
Psoriasis affects over 8 million Americans and more than 125 million people worldwide, making it one of the most commercially significant indications in dermatology and immunology. The treatment landscape has been transformed over two decades by the sequential approval of TNF inhibitors, IL-12/23 blockers, IL-17 inhibitors, IL-23 p19 inhibitors, and now oral TYK2 inhibitors — with each wave generating intense competitive activity in clinical development.
With hundreds of active psoriasis trials on ClinicalTrials.gov, monitoring new registrations is essential for pharma competitive intelligence, biotech investors, and dermatology researchers. Key signals to track:
- Next-generation IL-17 and IL-23 inhibitors — improved dosing, subtype selectivity, and safety profiles
- Oral TYK2 inhibitor programs following deucravacitinib (Sotyktu) approval — competitors and new mechanisms
- Combination trials exploring biologics with novel co-targets (e.g., IL-17 + IL-36, dual cytokine inhibitors)
- Psoriatic arthritis trials — a large and growing adjacent indication
- Biosimilar trials for established biologics (secukinumab, ixekizumab, adalimumab)
- Biomarker and precision medicine studies identifying responder/non-responder phenotypes
- Long-term extension studies reporting durability and safety data
Get daily psoriasis trial digest
Set your profile once. Receive a clean digest every morning with new trials and updates matching your criteria.
Get the Free DigestWhat we monitor for psoriasis
Our pipeline pulls directly from the ClinicalTrials.gov API every day. For a psoriasis watch profile, you can configure:
- Condition keywords: "psoriasis", "plaque psoriasis", "moderate-to-severe plaque psoriasis", "psoriatic arthritis", "psoriatic disease", "pustular psoriasis", "erythrodermic psoriasis"
- Phase filter: Phase 1 only, Phase 2/3, or all phases
- Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors
- Status filter: Recruiting only, all active studies, or any status
The psoriasis treatment landscape in 2026
IL-17 pathway: established leaders and next-generation challengers
The IL-17 axis remains the dominant target in moderate-to-severe plaque psoriasis. Secukinumab (Cosentyx, Novartis) and ixekizumab (Taltz, Eli Lilly) established IL-17A inhibition as the highest-efficacy standard; bimekizumab (Bimzelx, UCB) advanced the class further by inhibiting both IL-17A and IL-17F, demonstrating superior PASI 100 response rates. The pipeline now includes several next-generation IL-17 inhibitors with extended dosing intervals, subcutaneous auto-injector formulations, and improved immunogenicity profiles, each requiring Phase 2 and Phase 3 trials that are actively registering patients.
IL-23 p19 inhibitors: durability and long-term data
The IL-23 p19 selective inhibitors — guselkumab (Tremfya, J&J), risankizumab (Skyrizi, AbbVie), and tildrakizumab (Ilumya, Sun Pharma) — have differentiated on dosing convenience and long-term durability. Head-to-head and combination trials continue to generate data relevant to treatment sequencing decisions. AbbVie's Skyrizi has expanded aggressively into psoriatic arthritis and Crohn's disease, and monitoring its clinical program provides insight into pipeline prioritization across indications.
TYK2 inhibition: oral convenience enters the high-efficacy tier
Deucravacitinib (Sotyktu, Bristol Myers Squibb), the first approved TYK2 inhibitor, demonstrated PASI 75 rates superior to apremilast with a favorable safety profile relative to JAK inhibitors, given its allosteric mechanism. The approval has spurred a wave of competitive TYK2 inhibitor programs in clinical development, along with combination studies pairing TYK2 inhibition with biologics targeting complementary pathways. Tracking new TYK2 trial registrations is critical for companies and investors watching this emerging oral drug class.
Psoriatic arthritis: a large and underserved adjacent opportunity
Approximately 30% of psoriasis patients develop psoriatic arthritis, and the conditions share overlapping biology while requiring distinct efficacy endpoints. Many Phase 3 programs pursue simultaneous skin and joint indications. Monitoring psoriatic arthritis trials is particularly important for companies developing agents with dual dermatology/rheumatology ambitions, as joint outcomes data increasingly influences payer coverage and prescribing decisions across both indications.
Comorbidities and precision medicine
Psoriasis carries significant comorbidity burden — cardiovascular disease, metabolic syndrome, depression, and inflammatory bowel disease all occur at elevated rates. Clinical trials increasingly incorporate cardiovascular outcome endpoints, metabolic biomarkers, and patient-reported outcomes alongside the traditional PASI score. Biomarker studies seeking to predict biologic response are growing in number as the field moves toward precision prescribing and away from trial-and-error sequencing.
Who uses psoriasis trial monitoring
Pharma and biotech companies
Major players including J&J (Janssen), AbbVie, Novartis, UCB, Eli Lilly, and Bristol Myers Squibb maintain active psoriasis clinical programs and monitor competitor activity closely. BD teams track new Phase 1 and Phase 2 trial registrations to identify emerging mechanisms before data become public. Smaller biotechs building next-generation IL-17, IL-23, or TYK2 programs track the crowded landscape to identify differentiation opportunities and avoid head-to-head competition with incumbent approvals.
Dermatology researchers and academic centers
Academic dermatologists at major medical centers track new trial registrations to identify investigator-initiated trial opportunities, understand the competitive landscape for grant applications, and recruit patients into appropriate studies. Psoriasis is one of the most trial-rich dermatologic conditions, and staying current requires systematic monitoring rather than ad hoc searching.
Oncology and immunology investors
Investors with exposure to immunology assets — particularly companies in the IL-17, IL-23, or JAK/TYK2 spaces — monitor psoriasis trial activity as a leading indicator of clinical development strategy. A new Phase 2 trial registration often precedes a clinical readout or partnership announcement by 12–24 months, providing early competitive intelligence that informs portfolio positioning.
Frequently asked questions
How current is the psoriasis trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.
Can I track psoriasis and psoriatic arthritis separately?
Yes. On the Pro plan ($149/month), you can create multiple search profiles. You might have one profile for plaque psoriasis biologics, another for psoriatic arthritis Phase 3 trials, and another for oral small molecules — each delivering a focused daily digest.
Does this cover international psoriasis trials?
ClinicalTrials.gov includes trials conducted internationally, so yes — global psoriasis trials registered on ClinicalTrials.gov are included. Most major industry-sponsored programs, particularly those with US sites, are registered here, covering trials run in Europe, Asia, and Latin America.
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 13 tracked fields and tells you which one changed, with the old and new values, for every Psoriasis trial on your watchlist. Each change is classified as critical, notable, or minor, so a trial quietly adding a dozen new sites does not read the same as a contact-details edit.
Can I filter for specific drug mechanisms like TYK2 or IL-23?
Yes. You can include specific intervention keywords (e.g., "TYK2 inhibitor", "IL-23", "deucravacitinib") alongside condition keywords to narrow your daily digest to the mechanisms most relevant to your work.
300 active trials, 152 recruiting.
Industry sponsors run 137 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 69.
| Top industry sponsor | Active trials |
|---|---|
| Bristol-Myers Squibb | 14 |
| Johnson & Johnson / Janssen | 11 |
| AbbVie | 5 |
| Bausch Health Americas, Inc. | 4 |
| Novartis Pharmaceuticals | 4 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms… NCT06399432 | Recruiting | Completion pushed: 2026-07-01 → 2027-01-01 | 2026-09-05 |
| Cytokine Expression in Psoriasis Patients With and Without Joint Involvement NCT05307809 | Recruiting | Completion pushed: 2026-08-18 → 2027-02-18 | 2026-09-01 |
| A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe… NCT07724366 | Recruiting | Recruitment opened | 2026-09-10 |
| The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease NCT07487831 | Recruiting | Recruitment opened | 2026-09-10 |
| An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis NCT07449702 | Recruiting | Trial sites expanded: 26 → 32 locations | 2026-09-05 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.
Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list and landscape reports.
Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.